MedTrace Logo

n-3 Polyunsaturated Fatty Acids in Obesity

NCT00760760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-03-16

No results posted yet for this study

Summary

Inflammation in the adipose (fat) tissue is an important condition leading to metabolic derangements and cardiovascular disease in obese patients. n-3 polyunsaturated fatty acids exert anti-inflammatory effects and prevent adipose tissue inflammation in rodent obesity. This study tests the hypothesis that n-3 polyunsaturated fatty acids ameliorate adipose tissue inflammation in morbidly obese patients.

Conditions

  • Adipose Tissue Inflammation
  • Morbid Obesity

Interventions

DRUG

reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)

4g daily, 8 weeks

DRUG

control

equivalent amount of fat as butter

Sponsors & Collaborators

  • National Bank of Austria

    collaborator OTHER_GOV

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Thomas M Stulnig, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-09-30
Completion
2016-03-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760760 on ClinicalTrials.gov